Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.
about
The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeuticsEarly phase clinical trials to identify optimal dosing and safetyPhase I trials of antitumour agents: fundamental conceptsStatistical controversies in clinical research: requiem for the 3 + 3 design for phase I trialsEarly phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014A statistical evaluation of dose expansion cohorts in phase I clinical trials.Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.Dose expansion cohorts in Phase I trials.Phase 1 trial design: is 3 + 3 the best?Clinical trials: Early phase clinical trials-are dose expansion cohorts needed?The changing landscape of phase I trials in oncology.Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs.New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study.Evaluating the role of phase I expansion cohorts in oncologic drug development.Determinants of the recommended phase 2 dose of molecular targeted agents.Integrating the escalation and dose expansion studies into a unified Phase I clinical trial.Cancer immunotherapy trials: leading a paradigm shift in drug development.The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria.Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.Statistical controversies in clinical research: building the bridge to phase II-efficacy estimation in dose-expansion cohorts.Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs.Sequential monitoring of Phase I dose expansion cohorts.Design considerations for early-phase clinical trials of immune-oncology agents
P2860
Q26738677-2B24BDF0-FD70-49A0-8E04-01FBCD13DD3CQ26865076-352D0E46-549F-4BCA-ACB2-4B8FC6E3CE68Q26865346-944045AB-B588-4AC7-9335-6A6407E7AD2FQ27023178-BF7DDD77-2B19-422B-BF9D-533A93F7A186Q30234441-366FBB1F-4AF8-4DD6-AAD9-DDB19FE47240Q34499662-24A44B05-EB13-4A9F-AE87-C21594C6FFF7Q34535243-D1510AF7-835E-4CBA-9304-EAEDADECD5D0Q35136424-FE22D5C4-8362-4609-AC80-B98CA7DBC4E0Q36047412-F5FB91B2-057E-4483-82D0-BD7877137258Q36288987-5FBC6346-5695-44AF-BCE5-880E9715F5AEQ37158298-555AE3BC-832E-419A-ADE2-C1E18D36786AQ38222466-62ABECC7-A270-4EF6-BA4D-37262E755E32Q38543293-406231DC-D609-4370-9353-B2E2B3574F90Q38629203-D924A0E3-2329-4D6D-9E11-4DD653C4407CQ38752180-40ED0009-E3EE-431F-9B2E-3B7AAD9CB33AQ38888445-831C8F07-12BE-4D56-9148-5D0071464D14Q38975518-959AFFA2-65DD-42AC-B40C-EA96B451BC37Q39128248-F8062581-E84B-41A9-94FE-34DC8B8E3C59Q39620076-B597388F-0CDF-42E4-A048-AB926DBCC413Q42414063-D555039B-8D8B-4ED3-8AE7-B2F41CF92157Q43421550-D1AE2AAA-1A56-4F29-A4ED-60D32B86264BQ43846394-E8F2B66A-A28B-4975-B74A-6BA267AC7C66Q47364031-2FBE7DEF-467E-4953-8E04-AF40816B903FQ50749429-FA759A6C-9B8D-46D7-A9DE-C83FFC48BAEEQ54905594-2C760980-7454-4443-B172-6A4D4AFDD6AAQ56334001-DA5CE21C-AADB-4D90-827C-5723E6926CBB
P2860
Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Evolution of clinical trial de ...... e-agent phase I cancer trials.
@en
type
label
Evolution of clinical trial de ...... e-agent phase I cancer trials.
@en
prefLabel
Evolution of clinical trial de ...... e-agent phase I cancer trials.
@en
P2093
P50
P356
P1476
Evolution of clinical trial de ...... e-agent phase I cancer trials.
@en
P2093
Albiruni R Abdul Razak
Arif Manji
Ian F Tannock
Lillian L Siu
P304
P356
10.1200/JCO.2012.47.4957
P407
P577
2013-10-14T00:00:00Z